Becton, Dickinson and Company (NYSE:BDX) , popularly known as BD, in collaboration with Check-Points Health B.V., recently obtained CE Mark for molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the BD MAX System. This development is expected to strengthen BD’s foothold in molecular diagnostic business, globally.
Notably, Check-Points is a privately-owned diagnostics company, based in Wageningen, The Netherlands.
The BD MAX System is a fully-integrated, automated platform capable of providing results for up to 24 samples across multiple syndromes in less than three hours.
The BD MAX Check-Points CPO test provides detection of the five most common carbapenemase genes in less than 2.5 hours, compared with traditional methods, which may take up to 24 hours.
Early detection of the presence of such bacteria is crucial to execute proper infection control measures. The assay replaces an older version of the test from Check-Points, offering an improved workflow and additional target.
Becton, Dickinson and Company Price and Consensus
Becton, Dickinson and Company Price and Consensus | Becton, Dickinson and Company Quote
Prospects
Per management’s estimates, by the year 2050, antimicrobial resistance (AMR) can cause fatality of up to 10 million annually, if no precaution is taken. AMR is the ability of a microorganism to survive, despite being treated with effective antimicrobial drugs. Consequently, patients with such infections are prone to develop lethal complications.
Thus, spread of CPO is a major challenge toward the vigilance of antimicrobial diseases, due to the organisms’ ability to produce the enzyme carbapenemase.
The abundant prospects of global molecular diagnostics market are encouraging. According to a research by MarketsandMarkets, this market is projected to reach $10.12 billion by 2021 from $6.54 billion in 2016, at a CAGR of 9.1%.
Shares Shine Bright
BD has had a favorable run on the bourses over the last year. The stock has returned 31.4% compared with industry’s rally of 25.3%.
Zacks Ranks & Key Picks
Becton Dickinson carries a Zacks Rank #3 (Hold).
A few better-ranked stocks in the broader medical space are Bio-Rad Laboratories Inc. (NYSE:BIO) , Neogen Corporation (NASDAQ:NEOG) and Humana Inc. (NYSE:HUM) . All these stocks sport a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Bio-Rad has a massive projected growth rate of 141.46 percent for the first-quarter of 2018. The stock has outperformed the industry by returning 14.2% in the last three months.
Neogen has a long-term projected growth rate of 15%. In the last six months, the stock has gained 21.6%, surpassing its industry’s.
Humana has an expected growth rate of 15.6% in the first quarter of 2018. Over the last month, the stock has gained 9.7%, above the industry’s return.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple (NASDAQ:AAPL) sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>
Bio-Rad Laboratories, Inc. (BIO): Free Stock Analysis Report
Neogen Corporation (NEOG): Free Stock Analysis Report
Humana Inc. (HUM): Free Stock Analysis Report
Becton, Dickinson and Company (BDX): Free Stock Analysis Report
Original post